Effect of locally applied WEB 2086, a platelet-activating factor antagonist, on inflammatory skin conditions in mice

Kemény, Lajos; Трач, Володимир

doi:10.1007/bf02505242

Cited by 9 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therapeutic strategies to ameliorate the symptoms of radiation dermatitis comprise empirical topical regimens including powders, 5–7 dexpanthenol‐containing emollients 8,9 and topical corticosteroids 10–14 . Although various additional topical regimens have been reported to be either effective 15–28 or ineffective, 29–32 limited information is available from controlled trials 9 , 12–14,22 , 27,29–32 . Accordingly, to date there is no general agreement about how to treat or prevent radiation dermatitis 5,7 , 24,33 .…”

mentioning

confidence: 99%

Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study

Schmuth¹,

Wimmer

Hofer³

et al. 2002

Br J Dermatol

173

145

View full text Add to dashboard Cite

We provide evidence that prophylactic and ongoing use of topical therapy with either topical corticosteroid or a dexpanthenol-containing emollient ameliorates, but does not prevent radiation dermatitis. Our data suggest, but do not prove, a benefit of a topical corticosteroid vs. a dexpanthenol-containing emollient. Further controlled studies with larger cohorts will be needed to determine optimal forms of topical therapy for radiation dermatitis.

show abstract

mentioning

confidence: 99%

Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study

Schmuth¹,

Wimmer

Hofer³

et al. 2002

Br J Dermatol

173

145

View full text Add to dashboard Cite

show abstract

“…PAF-related activity has been detected in UVB-irradiated skin in both animal models and human subjects [5]. The local application of a specific receptor antagonist to the earlobe of mice successfully inhibited UV dermatitis [4]. In the present experiment on human volunteers the locally employed 3% WEB 2086 gel proved to be an effective anti-inflammatory agent in UV dermatitis.…”

Section: Discussionmentioning

confidence: 51%

“…The PAF receptor may be a pharmacologic target for UVB radiation in the skin and may thus augment the UVB-mediated production of cytokines such as IL-8 [3]. In a previous animal experimental model, we demonstrated that a PAF receptor antagonist has an antiinflammatory effect on UV-induced dermatitis [4]. The goal of our present experiment was to determine whether locally applied WEB 2086, a selective PAF receptor antagonist, alters the dermatitis-causing effect of UVB light on the human skin.…”

Section: Introductionmentioning

confidence: 73%

See 1 more Smart Citation

Platelet-Activating Factor Antagonist WEB 2086 Inhibits Ultraviolet-B Radiation-Induced Dermatitis in the Human Skin

Baltás

Трач²,

Kemény

2003

Skin Pharmacol Physiol

Self Cite

View full text Add to dashboard Cite

It has been suggested that platelet-activating factor (PAF) plays a role in the pathomechanisms of various inflammatory diseases. In an experimental animal model we demonstrated earlier that a selective PAF receptor antagonist gel inhibits ultraviolet-B (UVB) light-induced edema in mouse ears. The goal of our present investigation was to determine whether locally applied WEB 2086, a selective PAF receptor antagonist, alters the dermatitis-causing effect of UVB light on human skin. We induced dermatitis in healthy volunteers by irradiating their skin with UVB light in increasing doses. The irradiated area was treated with WEB 2086 gel (3%) or with a placebo. Erythema was measured spectrophotometrically after 24 and 48 h. After both 24 and 48 h, the WEB 2086 gel significantly inhibited the UVB light-induced erythema at each radiation dose in comparison with the placebo. The PAF antagonist gel therefore proved to be effective against UVB-induced dermatitis. Our results may help to understand the relative importance of mediators in UVB-induced dermatitis and might perhaps pave the way to better therapeutic modalities in this condition.

show abstract

Antiinflammatory activity of the platelet-activating factor receptor antagonist A-85783

Travers

Pei

et al. 1998

Archives of Dermatological Research

View full text Add to dashboard Cite

Accumulating evidence suggests an important role for the lipid mediator, platelet-activating factor (PAF), in cutaneous inflammation. In these studies the antiinflammatory effects of the potent and selective lipophilic PAF receptor antagonist A-85783 topically applied to the ventral ears of male Wistar rats were assessed. Intradermal injections of PAF into rat ears resulted in cutaneous inflammation as assessed by both ear thickness measurements and histological evaluation. Pretreatment of the ears with A-85783 resulted in an inhibition of subsequent PAF-induced inflammation. A-85783 treatment also inhibited phorbol myristic acetate-induced cutaneous inflammation, suggesting that the PAF receptor is involved in the etiology of this experimental dermatitis. These findings demonstrate that epicutaneous A-85783 is an appropriate tool to study the role of the PAF receptor in cutaneous inflammation, and suggest the possible clinical utility of this new class of antiinflammatory agents.

show abstract

Effect of locally applied WEB 2086, a platelet-activating factor antagonist, on inflammatory skin conditions in mice

Cited by 9 publications

References 13 publications

Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study

Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study

Platelet-Activating Factor Antagonist WEB 2086 Inhibits Ultraviolet-B Radiation-Induced Dermatitis in the Human Skin

Antiinflammatory activity of the platelet-activating factor receptor antagonist A-85783

Contact Info

Product

Resources

About